UCSF Custom Discovery
Research Platform
UCSF Custom Discovery is a platform for personalized cancer research and treatment. It profiles an individual patient's tumor and immune cells in depth to help their care team find matching existing drugs or point toward new custom therapies, in days to weeks.
Matthew Krummel, PhD · Cancer
Overview
Custom Discovery, a program of the UCSF Immunoprofiler and ImmunoX, offers personalized profiling of a patient's cancer to help patients and clinicians find novel or cutting-edge therapies. Working with the patient's clinicians to ensure good sample preparation, the team applies the same methods used in the Immunoprofiler's large cohort studies, including DNA and RNA sequencing of tumor cells and the surrounding immune cells and a large CITE-seq panel, on tumor, normal tissue, and blood. A rapid track returns results in about 1 to 3 days and a deeper track in 4 to 8 weeks. Findings, shared with the patient's care team, may identify existing drugs that match the tumor's biology or support custom therapies or vaccines, and a portion of each tumor is kept frozen to test future treatments. A cross-functional team of immunologists, biostatisticians, pathologists, and project managers works closely with each patient.
About the program
- Program type
- Expanded access program
- Also known as
- UCSF Custom Discovery: A platform for personalized cancer discovery and treatment
- Disease areas
- Cancer
Patients
- Profiled
- 25 patients, 2024 to 2026
- By year of enrollment
- 2024: 7 · 2025: 7 · 2026: 11
- Cancer types
- Rare cancers · 13Melanoma · 3Uterine leiomyosarcoma · 3Colorectal adenocarcinoma · 2Pancreatic ductal carcinoma · 2Prostate adenocarcinoma · 2
Shown in aggregate. Individual patient records are not published.
People and partners
- Lead
- Matthew Krummel, PhD
- Department
- Pathology
- Collaborators
- UCSF Immunoprofiler; ImmunoX